Oncology Drugs Market to Reach $555 Billion by 2035

Oncology drugs market was valued at $230 billion in 2025 and is projected to reach $555 billion by 2035, growing at a CAGR of 9.2% during 2026–2035. According to the U.S. FDA, zongertinib (Hernexeos), a kinase inhibitor, has received accelerated approval for the treatment of adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 (ERBB2) tyrosine kinase domain–activating mutations, as identified through an FDA-authorized diagnostic test. This approval extends its use to include patients who have not previously undergone systemic therapy. The decision was supported by results from the Beamion LUNG-1 trial, which demonstrated notable clinical efficacy in 72 patients based on objective response rate and duration of response. Under the FDA’s accelerated approval pathway, such oncology drugs are approved based on early clinical evidence, with the requirement of confirmatory trials to validate their long-term clinical benefit. This pathway enables faster patient access to innovative therapies while ensuring continued evaluation of safety and effectiveness. If subsequent trials confirm benefit, the drug may receive full approval; otherwise, its indication may be revised or withdrawn.

Browse the full report description of “Oncology Drugs Market Size, Share & Trends Analysis Report by Cancer Type (Lung, Breast, Colorectal, Prostate, Blood, Liver, Others), by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), by Molecule Type (Small Molecules, Biologics), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/oncology-drugs-market

Leading Players Accelerate Innovation in the Oncology Drugs Market

The key players in the oncology drugs market include Roche Holding AG, Amgen Inc., Merck & Co., Inc., Bristol Myers Squibb, and Eli Lilly and Company, among others. These companies are driving advancements across multiple cancer types through innovations in immunotherapy, targeted therapy, and biologics. Their focus on developing novel monoclonal antibodies, small-molecule drugs, and combination regimens is improving treatment efficacy and patient survival outcomes. Strategic investments in R&D and precision medicine are enabling personalized cancer treatments. Additionally, ongoing clinical trials and regulatory approvals are accelerating the adoption of next-generation oncology therapies globally.

• In March 2026, GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), received Orphan Drug Designation in Japan for the treatment of small-cell lung cancer (SCLC). The designation was supported by early clinical data from the ARTEMIS-001 trial, demonstrating durable responses in patients with extensive-stage SCLC. This marks another key regulatory milestone for the therapy, which is advancing in global clinical development.
• In March 2026, Bristol Myers Squibb’s cancer immunotherapy Opdivo (nivolumab) received expanded approvals in both the S. and European Union for new indications in classical Hodgkin lymphoma, including use with chemotherapy for previously untreated advanced disease and in combination with other agents for relapsed or refractory cases, marking a significant advance in treatment options.
• In November 2025, Roche announced that its investigational oral selective estrogen receptor degrader giredestrant demonstrated a statistically significant improvement in invasive disease?free survival compared with standard endocrine therapy for early-stage ER-positive, HER2-negative breast cancer, potentially establishing a new standard of care.

• In September 2024, Pfizer Inc. highlighted its diverse oncology portfolio and combination therapy approaches at ESMO 2024, featuring more than 50 research abstracts covering approved and investigational treatments across tumour types. The company showcased longer?term data for BRAFTOVI + MEKTOVI in BRAF?mutant metastatic NSCLC and encouraging early results for novel antibody?drug conjugates (ADCs) and CDK inhibitors, underscoring its commitment to advancing targeted and immuno?oncology therapies.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Cancer Type
• By Drug Class
• By Molecule Type
• Regions Covered
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Johnson and Johnson, AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co., Inc., and Bristol Myers Squibb, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Oncology Drugs Market Report Segment

By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Blood Cancer
• Liver Cancer
• Others

By Drug Class

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormonal Therapy

By Molecule Type

• Small Molecules
• Biologics

Global Oncology Drugs Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/oncology-drugs-market